Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prince Pharmaceutical CoROCO:6935 -0.50%60 FCF Margin % is 12.36% as of Dec. 2025, which is 5050% above its 10-year median of 0.24. GuruFocus rates ROCO:6935 with a GF Score™ of 60/100 and a GF Value™ of NT$42.11 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 963 Drug Manufacturers companies, Prince Pharmaceutical Co ranks better than 61.58% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Prince Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prince Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prince Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Prince Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prince Pharmaceutical Co (ROCO:6935) has a FCF Margin % of 12.36% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Prince Pharmaceutical Co and its competitors. This is 5050% above median its historical median of 0.24. According to the industry distribution chart, Prince Pharmaceutical Co ranks #370 out of 963 companies in the Drug Manufacturers industry, placing it in the top 38.4%.
Is Prince Pharmaceutical Co's FCF Margin % too high?
Prince Pharmaceutical Co's current FCF Margin % of 12.36% is 5050% above median its 10-year median of 0.24. The Drug Manufacturers industry median FCF Margin % is 2.57. Prince Pharmaceutical Co's value of 12.36% is 380.9% above this industry median. Based on the distribution chart, Prince Pharmaceutical Co ranks #370 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prince Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Prince Pharmaceutical Co ranks #370 out of 963 companies for FCF Margin %. This puts Prince Pharmaceutical Co in the upper half of its industry. The industry median FCF Margin % is 2.57. Prince Pharmaceutical Co's value of 12.36% is 380.9% above this benchmark. While the company's 10-year median is 0.24 vs. the industry median of 2.57, Prince Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prince Pharmaceutical Co's current FCF Margin % of 12.36% is 380.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Prince Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prince Pharmaceutical Co's current FCF Margin % is 12.36%, which is 5050% above median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$42.11, compared to a current price of NT$30.15 — trading 28.4% below its estimated fair value. The current FCF Margin % is 12.36%, which is 5050% above median its 10-year median of 0.24 and 380.9% above the Drug Manufacturers industry median of 2.57. Prince Pharmaceutical Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current FCF Margin % is 12.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?
Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$30.15 is trading 28.4% below its estimated GF Value™ of NT$42.11.
GuruFocus considers Prince Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for ROCO:6935:
FCF Margin %: 12.36% (5050% above median its 10-year median of 0.24)
GF Value™: NT$42.11 vs. price of NT$30.15 (28.4% below fair value)
Industry Position: 380.9% above the Drug Manufacturers median (#370 of 963)
No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
60GF Score
Get the complete analysis for ROCO:6935
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6935 has been successfully added to your 
